Rontalizumab, a novel monoclonal antibody , demonstrates promising scope in targeting particular inflammatory pathways. This cutting-edge treatment exhibits the chance to block interleukin-6 receptor (IL-6R), https://www.targetmol.com/compound/rontalizumab